Learning Objectives:
- To discuss the pharmacologic differences of GLP1 products for obesity
- To discuss efficacy of different GLP1 products in bariatric and non-bariatric populations
- To debate use of medications with cardiovascular implications (DOAC, GLP-1, SGLT2) in the post-bariatric surgery population
| 8:00am |
GLP-1 Considerations for the Bariatric Surgical Practice Scott V Monte, PharmD |
| 8:30am |
Medications with Cardiovascular Implications after Bariatric Surgery Nicholas Norgard, PharmD |
| 9:15am |
Debate / Q&A Session |
| 9:30am | Adjourn |